Bruteridin(bergamot juice) / MAPK Cancer Research Results

Brut, Bruteridin(bergamot juice): Click to Expand ⟱
Features:

Bruteridin is a bergamot-derived HMG-bearing flavanone neohesperidoside isolated from Citrus bergamia fruit and best understood as a specialized citrus polyphenol rather than a cardiac glycoside or classic anticancer drug. It is commonly discussed together with the closely related compound melitidin and occurs within bergamot juice or bergamot polyphenolic fractions rather than as a clinically deployed purified agent. Functionally, it is most strongly linked to statin-like HMG-CoA reductase interaction, with broader antioxidant, anti-inflammatory, and metabolic effects generally attributed to bergamot mixtures. No approved oncology use or standard abbreviation is established for purified bruteridin.

Primary mechanisms (ranked):

  1. HMG-CoA reductase binding and mevalonate-pathway suppression potential
  2. Polyphenol-associated anti-inflammatory and redox-modulatory activity in bergamot mixtures
  3. Indirect effects on mitochondrial function, autophagy, and metabolic stress pathways when delivered as part of bergamot polyphenolic fractions
  4. Possible anticancer contribution within bergamot extracts, but not yet isolated mechanistically for purified bruteridin

Bioavailability / PK relevance: Dedicated human PK data for purified bruteridin are lacking. After bergamot juice intake, circulating species detected in humans are mainly phase II conjugates of hesperetin, naringenin, and eriodyctiol derivatives, indicating substantial intestinal/hepatic transformation of bergamot flavanones rather than demonstrated sustained intact systemic bruteridin exposure.

In-vitro vs systemic exposure relevance: Most cancer-relevant data come from bergamot juice/extract studies using complex mixtures at mg/mL-range in vitro, which should not be assumed to reflect achievable free systemic concentrations of purified bruteridin. The translational bridge from bergamot mixture exposure to isolated bruteridin anticancer activity remains weak.

Clinical evidence status: For cancer, evidence for bruteridin itself is preclinical/inferential only. Human data exist for bergamot extracts in cardiometabolic settings, not for purified bruteridin as an anticancer agent. At present this is best categorized as preclinical and mixture-based, with no oncology RCT or approved therapeutic deployment for the isolated compound.

Mechanistic relevance table

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 HMG-CoA reductase and mevalonate pathway ↓ mevalonate signaling potential ↓ cholesterol synthesis potential R-G Metabolic growth restraint Best-supported direct mechanism for bruteridin. Evidence is strongest from isolation and computational binding work showing statin-like structural/active-site compatibility, but direct cancer-cell validation for purified bruteridin is limited.
2 Inflammatory signaling ↓ NF-κB-linked inflammatory tone (context-dependent) ↓ inflammatory stress G Microenvironment modulation Supported mainly at bergamot extract or bergamot polyphenolic fraction level, not cleanly assigned to bruteridin alone.
3 Mitochondrial stress and autophagy ↔ or ↑ stress susceptibility (context-dependent) ↔ or ↓ injury in non-malignant stress models G Metabolic stress remodeling Bergamot mixtures modulate mitochondrial function and autophagy in hepatic and cardiovascular models. Bruteridin may contribute indirectly, but isolated evidence is insufficient.
4 ROS balance ↔ (not established for purified bruteridin) ↔ (not established for purified bruteridin) R-G Context-dependent redox modulation CRC studies with bergamot juice extract show ROS increase and apoptosis, but these results cannot be attributed specifically to bruteridin.
5 Apoptosis and cell-cycle control ↑ apoptosis potential (mixture-level evidence) ↔ G Antiproliferative pressure Observed in bergamot juice extract models of colorectal cancer; purified bruteridin-specific evidence is currently absent.
6 Clinical Translation Constraint Low direct evidence Unknown purified-agent safety margin G Translation limited by evidence gap Main constraints are lack of purified-bruteridin oncology studies, uncertain intact oral exposure, reliance on bergamot mixtures, and potential bergamot-associated drug-interaction concerns from co-occurring furanocoumarins in some preparations.

TSF: P: 0–30 min
R: 30 min–3 hr
G: >3 hr
MAPK, mitogen-activated protein kinase: Click to Expand ⟱
Source: CGL-CS
Type:
Mitogen-activated protein kinases (MAPKs) are a group of proteins involved in transmitting signals from the cell surface to the nucleus, playing a crucial role in various cellular processes, including growth, differentiation, and apoptosis (programmed cell death).

MAPK Pathways: The MAPK family includes several pathways, the most notable being:
1.ERK (Extracellular signal-Regulated Kinase): Often associated with cell proliferation and survival.
2.JNK (c-Jun N-terminal Kinase): Typically involved in stress responses and apoptosis.
3.p38 MAPK: Associated with inflammatory responses and apoptosis.

Inhibitors: Targeting the MAPK pathway has become a strategy in cancer therapy. For example, BRAF inhibitors (like vemurafenib) are used in treating melanoma with BRAF mutations.
Altered Expression Levels:
Overexpression: Many cancers exhibit overexpression of MAPK pathway components, such as RAS, BRAF, and MEK. This overexpression can lead to increased signaling activity, promoting cell proliferation and survival.
Downregulation: In some cases, negative regulators of the MAPK pathway (e.g., MAPK phosphatases) may be downregulated, leading to enhanced MAPK signaling.
The expression levels of MAPK pathway components can serve as biomarkers for cancer diagnosis, prognosis, and treatment response. For example, high levels of phosphorylated ERK (p-ERK) may indicate active MAPK signaling and poor prognosis in certain cancers.

Numerous reports indicate that the MAPK pathway plays a major role in tumor progression and invasion, while inhibition of MAPK signaling reduces invasion.
Scientific Papers found: Click to Expand⟱
5706- Brut,    Bergamot juice extract inhibits proliferation by inducing apoptosis in human colon cancer cells
- in-vitro, CRC, HT29
TumCG↓, MAPK↓, TumCCA↑, Apoptosis↑, ROS↑, DNAdam↑, AntiCan↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

ROS↑, 1,  

Cell Death ⓘ

Apoptosis↑, 1,   MAPK↓, 1,  

DNA Damage & Repair ⓘ

DNAdam↑, 1,  

Cell Cycle & Senescence ⓘ

TumCCA↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

TumCG↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 1,  
Total Targets: 7

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: MAPK, mitogen-activated protein kinase
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:270  Target#:181  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page